Skip to main content

Chronic Obstructive Pulmonary Disease clinical trials at UC Davis

6 research studies open to eligible people

Showing trials for
  • A Study of Experimental Inhaled Treprostinil For Pulmonary Hypertension due to COPD

    open to eligible people ages 18 years and up

    The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks of active treatment in participants with PH-COPD.

    Sacramento, California and other locations

  • A Study of Experimental Nuvaira Lung Denervation System in COPD

    open to eligible people ages 40 years and up

    The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.

    Sacramento, California and other locations

  • A Study of Experimental Tezepelumab for Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

    open to eligible people ages 40-80

    A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    Sacramento, California and other locations

  • A Study of the Experimental Medicine Alvelestat (MPH966) for Chronic Obstructive Pulmonary Disease (COPD)

    open to eligible people ages 18-75

    The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare variant phenotype/genotype alpha-1 anti-trypsin deficient lung disease. Change in a number of different blood and sputum biomarkers related to lung damage, inflammation and elastase activity will be measured over a 12 week period. The effect on lung function and respiratory symptoms will also be measured.

    Sacramento, California and other locations

  • Experimental Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)

    open to eligible people ages 40 years and up

    A multi-center, randomized, 36-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.

    Sacramento, California and other locations

  • RejuvenAir® System Trial for Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

    open to eligible people ages 40-80

    Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air within the lungs and is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in terms of mortality. Chronic bronchitis (CB) is a common clinical phenotype within the umbrella of a COPD diagnosis and is classically defined as chronic cough and sputum production for 3 months a year for 2 consecutive years2, but many studies have used different definitions to define it- chronic cough and sputum production for one year or cough and sputum production on most days of the week. CB is associated with multiple clinical consequences, including; the worsening of lung function decline, increasing risk of acute exacerbations of COPD, increased risk of developing pneumonia, reduced health related quality of life, and an increase in all-cause mortality.

    Sacramento, California and other locations

Last updated: